# A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants

> **NCT06086626** · PHASE2 · COMPLETED · sponsor: **Shionogi** · enrollment: 30 (actual)

## Conditions studied

- Gram-Negative Bacterial Infections

## Interventions

- **DRUG:** Cefiderocol
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT06086626
- **Lead sponsor:** Shionogi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-14
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06086626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06086626, "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06086626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*